Table 2.
Clinical Characteristics During Follow-up Stratified by Incident Hypertension
| Characteristic | All Patients (n = 3141) | Hypertension (n = 756) | No Hypertension (n = 2385) |
|---|---|---|---|
| BMI maximum, kg/m2 | |||
| Median (IQR) | 27.7 (24.5–30.2) | 28.5 (25.4–33.1) | 27.5 (24.2–29.5) |
| >30, n (%) | 859 (27) | 308 (41) | 551 (23) |
| BMI meana, kg/m2 | |||
| Median (IQR) | 26.2 (22.7–28.7) | 26.8 (23.6–30.3) | 25.9 (22.3–28.3) |
| >30, n (%) | 565 (18) | 209 (28) | 356 (15) |
| Creatinine maximum ≥1.4, n, (%) | 708 (23) | 230 (30) | 478 (20) |
| Creatinine most recent ≥1.4, n (%) | 232 (7) | 78 (10) | 154 (6) |
| CD4 nadir, cells/mm3 | |||
| Median (IQR) | 168 (36–352) | 153 (30–325) | 175 (38–362) |
| CD4 most recent, cells/mm3 | |||
| Median (IQR) | 436 (208–682) | 446 (266–664) | 433 (190–688) |
| HIV-1 VL most recent, <400 copies/mL, n (%) | 1859 (59) | 485 (64) | 1374 (57) |
| Ever on ART, n (%) | 692 (92) | 2144 (90) | |
| ART exposure (y)b, Median (IQR) | 4.80 (2.21–9.01) | 4.95 (2.38–9.15) | 4.26 (1.74, 8.41) |
| PI use ever, n (%) | 2774 (88) | 685 (91) | 2089 (88) |
Abbreviations: ART, antiretroviral therapy; BMI, body mass index; HIV-1, human immunodeficiency virus type 1; IQR, interquartile range; PI, protease inhibitor; VL, viral load.
a Average body mass index over follow-up period.
b Among persons initiated on ART.